Moffitt at SITC
Moffitt Cancer Center’s research focuses on cutting-edge discoveries that can be rapidly translated into improved diagnostic, preventive and therapeutic advances. As pioneers of immunotherapy as a groundbreaking cancer treatment, we were excited to participate in the Society for Immunotherapy of Cancer Annual Meeting from November 8-12. The studies our scientists presented explored many advances in areas like radiomics, checkpoint inhibitors and TIL therapy covering many cancer types.
2022 Featured Articles
Cellular Therapy May Be Viable Option for Advanced Melanoma Patients
Nearly one-third of patients respond to a single infusion of tumor infiltrating lymphocytes.
Using AI to Dictate Treatment for Non-Small Cell Lung Cancer
Data presented at the Society for Immunotherapy of Cancer shows AI can perform biomarker tests.
New Immunotherapy Could Be on the Horizon for Ovarian Cancer
Understanding tertiary lymphoid structures could unlock new treatments for a variety of cancers.
Phase 2 Bladder Cancer Trial Shows Promising Results
Updated data were presented at the 2022 SITC Annual Meeting.
For additional information on Moffitt’s research presented at SITC please reach out to:
Kim Polacek, APR, CPRC
Senior PR Account Coordinator